COBAS HCV TEST

Assay, Hybridization And/or Nucleic Acid Amplification For Detection Of Hepatitis C Rna,hepatitis C Virus

FDA Premarket Approval P150015

This medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original pma or panel track supplement and may not represent the most recent labeling.

Pre-market Approval Supplement Details

Approval for the cobas hcv. This device is indicated for: cobas hcv is an in vitro nucleic acid amplification test for both the detection and quantitation of hepatitis c virus (hcv) rna, in human edta plasma or serum, of hcv antibody positive or hcv-infected individuals. Specimens containing hcv genotypes 1 to 6 are validated for detection and quantitation in the assay. Cobas hcv is intended for use as an aid in the diagnosis of hcv infection in the following populations: individuals with antibody evidence of hcv with evidence of liver disease, individuals suspected to be actively infected with hcv antibody evidence, and individuals at risk for hcv infection with antibodies to hcv. Detection of hcv rna indicates that the virus is replicating and therefore is evidence of active infection. Cobas hcv is intended for use as an aid in the management of hcv-infected patients undergoing anti-viral therapy. The assay can be used to measure hcv rna levels at baseline, during treatment, at the end of treatment, and at the end of follow up of treatment to determine sustained or non-sustained viral response. The results must be interpreted within the context of all relevant clinical and laboratory findings. Cobas hcv has not been approved for use as a screening test for the presence of hcv in blood or blood products. Assay performance characteristics have been established for individuals treated with certain direct-acting antiviral agents (daa) regimens. No information is available on the assays predictive value when other daa combination therapies are used.

DeviceCOBAS HCV TEST
Classification NameAssay, Hybridization And/or Nucleic Acid Amplification For Detection Of Hepatitis C Rna,hepatitis C Virus
Generic NameAssay, Hybridization And/or Nucleic Acid Amplification For Detection Of Hepatitis C Rna,hepatitis C Virus
ApplicantRoche Molecular Systems, Inc.
Date Received2015-04-27
Decision Date2015-10-14
Notice Date2015-11-03
PMAP150015
SupplementS
Product CodeMZP
Docket Number15M-4018
Advisory CommitteeMicrobiology
Expedited ReviewNo
Combination Product No
Applicant Address Roche Molecular Systems, Inc. 4300 Hacienda Drive pleasanton, CA 94588-2722
Summary:Summary of Safety and Effectiveness
Labeling: Labeling
Approval Order: Approval Order

Supplemental Filings

Supplement NumberDateSupplement Type
P150015Original Filing
S043 2021-05-18 Special (immediate Track)
S042 2020-11-13 30-day Notice
S041 2020-09-17 Special (immediate Track)
S040 2020-07-27 30-day Notice
S039
S038 2020-04-17 30-day Notice
S037 2020-01-10 30-day Notice
S036 2019-11-29 30-day Notice
S035 2019-09-20 30-day Notice
S034 2019-08-30 30-day Notice
S033 2019-08-06 30-day Notice
S032
S031 2019-05-09 30-day Notice
S030 2019-05-09 30-day Notice
S029 2019-04-24 30-day Notice
S028 2019-04-24 30-day Notice
S027 2019-04-10 30-day Notice
S026 2019-04-08 30-day Notice
S025 2019-04-03 30-day Notice
S024 2019-03-27 30-day Notice
S023 2018-12-14 30-day Notice
S022 2018-11-13 30-day Notice
S021 2018-11-09 30-day Notice
S020 2018-08-21 30-day Notice
S019
S018 2018-07-27 30-day Notice
S017 2018-06-29 30-day Notice
S016 2018-06-08 30-day Notice
S015 2018-06-04 30-day Notice
S014 2018-04-16 30-day Notice
S013 2018-03-01 30-day Notice
S012 2018-01-23 30-day Notice
S011 2017-11-22 30-day Notice
S010 2017-10-30 30-day Notice
S009 2017-09-27 30-day Notice
S008 2017-09-26 30-day Notice
S007 2017-07-14 30-day Notice
S006 2017-05-09 30-day Notice
S005 2016-11-22 Special (immediate Track)
S004 2016-08-08 Real-time Process
S003 2016-07-08 30-day Notice
S002 2016-04-07 30-day Notice
S001 2016-02-26 30-day Notice

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.